UK Drug Body Backs Thalidomide, Velcade in Multiple Myeloma

The UK’s health-care cost-effectiveness body Wednesday backed publicly funded use of Celgene Corp.’s thalidomide and Johnson & Johnson’s bortezomib on the National Health Service for treating a type of bone marrow cancer called multiple myeloma.
The Wall Street Journal